News

The cash-cum-stock deal between Takeda and Shire was signed in May 2018 in a move to create a global, values-based research and development (R&D) driven biopharma company headquartered

Crizanlizumab (SEG101) is a humanized anti-P-selectin monoclonal antibody being studied to restrict VOCs in SCD. The status has been provided based on positive data from the phase II

These new candidates target rare genetic chronic diseases. According to the agreement, CANbridge has an exclusive regional or global rights for these therapies. WuXi Biologics will receive upfront,

The company’s drug pipeline also includes an IND-ready therapeutic candidate for Alzheimer’s disease. These two candidates are based on extensive clinical and/or preclinical R&D originally conducted by Dong-A

Loxo Oncology is engaged in the development and commercialization of highly selective drug candidates for patients with genomically defined cancers. The company is developing targeted drugs that are

PCI will add expanded Biotech clinical and commercial packaging and release testing capability at its Center of Excellence in Philadelphia, as well as expanded Cold Chain capacity at

Catalent will use the investment to enhance drug substance manufacturing capacity and drug product fill/finish capacity at its biologics manufacturing sites in Madison of Wisconsin and Bloomington of

CytoReason will receive from Pfizer payments potentially equaling up to low double digit millions of US$ for technology access fees, research support and certain success-based payments. CytoReason’s proprietary

As per the agreement, US-based Gilead will buy worldwide rights, with the exception of South Korea, to develop and commercialize novel small molecules against two undisclosed targets. In